rituximab,ibrutinib,Bendamustine
biogen,roche,novartis,janssen,abbvie
['shine', 'ibru']
#asco22 pres and publication of shine by of first-line ibrutinib + br in mcl: n=523; med age 71 (range 65-87) mpfs w/ ibr+br vs placebo+br: 80.6 vs 52.9 mo (hr 0.75; p = .01) os similar between arms g3/4 aes: 81.5% w/ ibr+br vs 77.3% placebo+br 
CME experts Sara Fagerlie, PhD, CHCP and Mindy Tanzola, PhD founded Front Row CME to help clinicians and educators manage the oncology information deluge.